Developer docs
API playgroundTry for free, no card

Search company profiles

ChemLex

Full company profile

uuid0002jwi

Namestring
ChemLex
Legal namestring
ChemLex Ltd.
Websiteurl
chemlex.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

ChemLex is a chemical synthesis contract research organization founded in 2022 by Magera Technology that operates an integrated AI-for-science platform combining proprietary dry lab AI models with a fully automated wet lab robotics system. The dry lab consists of three named proprietary AI modules — RetroPlanner for retrosynthesis route design, Reaction Condition Recommender for experimental condition optimization, and LCMS AutoAnalyzer for spectrum interpretation and purification recommendation — claimed to have "passed the Turing Test for chemistry." The wet lab operates five interconnected automation platforms (high-throughput experimentation at 1000+ reactions per day, auto-analytical, auto-separation, auto-work-up, and auto-flow chemistry), forming a closed-loop system in which robots execute experiments and feed structured data back into continuous model training. The platform runs 24/7 as a self-driving drug discovery laboratory in Singapore, where the company relocated its global headquarters in December 2025.

The company serves over 70 customers including six of the world's top ten global pharmaceutical firms, with commercial expansion into chemicals, semiconductors, automotive, and life sciences sectors. ChemLex generates revenue through what it describes as subscription/recurring AI-driven chemical discovery platform services, though specific pricing is not publicly disclosed. Go-to-market is direct enterprise field sales targeting large pharma, chemicals, and electronics firms, supplemented by strategic partnerships — notably an MoU with Merck KGaA for automated chemistry in life sciences and electronics, and an MoU with Singapore's Experimental Drug Development Centre for public-sector drug discovery. The company has raised approximately $104.5 million across three funding rounds (Jan 2024, Apr 2025, Dec 2025), with the most recent $45M round led by Granite Asia funding the Singapore expansion and headcount growth in engineering and chemistry.

Short descriptiontext

ChemLex is an AI-for-science chemical synthesis CRO that combines proprietary dry lab AI models (RetroPlanner, Reaction Condition Recommender, LCMS AutoAnalyzer) with an automated wet lab capable of 1000+ reactions daily, serving 70+ enterprise customers including six of the world's top ten pharmaceutical firms from its Singapore headquarters.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI-driven drug discovery, automated chemical synthesis, AI retrosynthesis platform, high-throughput experimentation, contract research services
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAIAD
Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations)
NAICS code1 code
  • Medical Laboratories621511
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
AI-Driven Drug Discovery and Automated Chemical Synthesis
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AI-driven chemical discovery platform services
TypeSubscription Recurring
Description

ChemLex provides AI-powered chemical synthesis and discovery services to pharmaceutical and chemical companies through its autonomous chemistry platform. The company serves over 70 customers including six of the top ten pharmaceutical firms globally.

technode.global
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

ChemLex operates an AI-driven chemical synthesis contract research organization that delivers compounds to clients using proprietary AI retrosynthesis models and a high-throughput automated wet lab platform. The platform combines a dry lab of AI models for retrosynthesis planning, reaction condition recommendation, and LCMS spectrum interpretation with a fully automated wet lab that conducts up to 1000+ reactions per day in a closed-loop system. The company serves pharmaceutical, biotechnology, chemicals, semiconductors, and automotive clients with a 24/7 self-driving drug discovery laboratory.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 1000+ reactions per day capacity
+2 more records
Product overview1 text field

ChemLex offers an integrated AI-for-science platform combining a dry lab of proprietary AI models with a fully automated wet lab. The dry lab comprises three core AI modules: RetroPlanner (AI retrosynthesis for designing synthetic routes), Reaction Condition Recommender (generating optimal reaction conditions), and LCMS AutoAnalyzer (interpreting spectra and recommending purification). The wet lab provides five interconnected automation platforms: High-Throughput Experimentation (HTE), Auto-Analytical, Auto-Separation, Auto-Work-up, and Auto-Flow Chemistry — all feeding a closed-loop system where robots collect experimental data that continuously trains the AI models. The company operates a 24/7 self-driving drug discovery laboratory in Singapore, serving over 70 customers including six of the world's top ten pharmaceutical firms. Partnerships, including an MoU with Merck KGaA, expand the platform's reach into life science and electronics research workflows.

Product and service5 records
1RetroPlanner
CategoryAI Retrosynthesis Software
Description

AI retrosynthesis model that autonomously designs optimal synthetic routes for target molecules for pharmaceutical and chemical industry clients.

2Reaction Condition Recommender
CategoryAI Reaction Optimization Software
Description

AI module that recommends optimal reaction conditions for chemical synthesis, integrated into ChemLex's closed-loop AI and automation platform.

3LCMS AutoAnalyzer
CategoryAI Spectrum Analysis Software
Description

AI-powered module that automatically interprets LCMS spectra and recommends purification conditions, operating as part of ChemLex's dry lab analytical capabilities for chemistry research customers.

4High-Throughput Experimentation (HTE) Platform
CategoryAutomated Laboratory Platform
Description

Wet lab automation platform supporting 8/40/500 mL reaction vials, heating and light reactions, capable of conducting up to 1000+ reactions per day for chemical synthesis customers.

5Self-Driving Drug Discovery Laboratory
CategoryAutonomous Chemistry Laboratory Service
Description

24/7 autonomous chemistry laboratory in Singapore combining AI-driven dry lab models with fully automated wet lab operations to accelerate pharmaceutical chemical discovery for customers including six of the world's top ten pharmaceutical firms.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Merck and ChemLex signed a Memorandum of Understanding to collaborate on advancing automated chemistry and research workflows in life science and electronics. The partnership aims to integrate AI-driven automation to accelerate discovery and innovation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-20
Description

Merck KGaA is using AI as a critical enabler for drug and materials discovery and has signed an MoU with ChemLex Ltd. for AI-driven automated chemical synthesis.

3Singapore's Experimental Drug Development Centre
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-08
Description

ChemLex signed a memorandum of understanding with Singapore's Experimental Drug Development Centre to advance next-generation small molecule drug discovery through AI-driven automation.

pressreleasehub.pa.media
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Publicly listed AI-driven computational chemistry and molecular simulation platform serving pharma customers. Directly comparable to ChemLex in retrosynthesis, reaction prediction, and drug-discovery AI capabilities, though Schrödinger is more software-centric without integrated wet-lab robotics at ChemLex's scale.

TypeDirect peer
Description

China-founded AI + robotics drug discovery company combining computational chemistry with automated wet-lab experimentation. Closest direct peer to ChemLex in combining dry-lab AI models with high-throughput robotic synthesis, also serving global pharma customers.

TypeDirect peer
Description

AI-driven drug discovery company applying generative AI and deep learning to target identification, chemistry, and clinical development. Comparable to ChemLex in pursuing AI-for-pharma, with overlapping pharma customer base and similar end-to-end platform ambition.

TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine-learning models in a closed-loop platform. Directly comparable to ChemLex's dry-lab/wet-lab integration model, though Recursion's pipeline is more biased toward phenotypic screening and internal pipeline development.

TypeDirect peer
Description

AI-driven precision medicine company applying AI to small-molecule drug design and discovery with major pharma partnerships. Comparable to ChemLex in serving top-tier pharma customers with AI-generated compounds, though with less emphasis on integrated wet-lab automation.

TypeDirect peer
Description

AI-based small-molecule drug discovery company using convolutional neural networks for hit identification and optimization. Comparable to ChemLex in applying AI to chemistry and pharma R&D, with a similar enterprise sales motion into pharma customers.

TypeEmerging player
Description

AI-driven protein engineering company combining machine learning with robotic wet-lab experimentation in a closed-loop system. Closely analogous to ChemLex in dry-lab/wet-lab integration, though focused on biologics rather than small-molecule synthesis.

TypeEmerging player
Description

Cloud-based lab automation platform enabling high-throughput experimental workflows in life sciences. Comparable to ChemLex in automating wet-lab chemistry, though focused on workflow software rather than AI retrosynthesis or integrated service delivery.

TypeEmerging player
Description

Provider of high-throughput automated synthesis workstations and robotic platforms for chemistry R&D. Comparable to ChemLex in providing automated synthesis infrastructure, though Chemspeed is primarily a tools vendor rather than a service provider.

10Iambic Therapeutics
TypeEmerging player
Description

AI-driven drug discovery company combining physics-based modeling with generative AI for small-molecule design. Comparable to ChemLex in AI-pharma focus and use of internally generated data to improve models, with a similar enterprise-customer motion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ChemLex

AI-Driven Drug Discovery and Automated Chemical Synthesischemlex.com

ChemLex is an AI-for-science chemical synthesis CRO that combines proprietary dry lab AI models (RetroPlanner, Reaction Condition Recommender, LCMS AutoAnalyzer) with an automated wet lab capable of 1000+ reactions daily, serving 70+ enterprise customers including six of the world's top ten pharmaceutical firms from its Singapore headquarters.

What ChemLex does

ChemLex is a chemical synthesis contract research organization founded in 2022 by Magera Technology that operates an integrated AI-for-science platform combining proprietary dry lab AI models with a fully automated wet lab robotics system. The dry lab consists of three named proprietary AI modules — RetroPlanner for retrosynthesis route design, Reaction Condition Recommender for experimental condition optimization, and LCMS AutoAnalyzer for spectrum interpretation and purification recommendation — claimed to have "passed the Turing Test for chemistry." The wet lab operates five interconnected automation platforms (high-throughput experimentation at 1000+ reactions per day, auto-analytical, auto-separation, auto-work-up, and auto-flow chemistry), forming a closed-loop system in which robots execute experiments and feed structured data back into continuous model training. The platform runs 24/7 as a self-driving drug discovery laboratory in Singapore, where the company relocated its global headquarters in December 2025.

The company serves over 70 customers including six of the world's top ten global pharmaceutical firms, with commercial expansion into chemicals, semiconductors, automotive, and life sciences sectors. ChemLex generates revenue through what it describes as subscription/recurring AI-driven chemical discovery platform services, though specific pricing is not publicly disclosed. Go-to-market is direct enterprise field sales targeting large pharma, chemicals, and electronics firms, supplemented by strategic partnerships — notably an MoU with Merck KGaA for automated chemistry in life sciences and electronics, and an MoU with Singapore's Experimental Drug Development Centre for public-sector drug discovery. The company has raised approximately $104.5 million across three funding rounds (Jan 2024, Apr 2025, Dec 2025), with the most recent $45M round led by Granite Asia funding the Singapore expansion and headcount growth in engineering and chemistry.

ChemLex firmographics

Firmographics
Name
ChemLex
Legal name
ChemLex Ltd.
Website
https://chemlex.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
ChemLex is an AI-for-science chemical synthesis CRO that combines proprietary dry lab AI models (RetroPlanner, Reaction Condition Recommender, LCMS AutoAnalyzer) with an automated wet lab capable of 1000+ reactions daily, serving 70+ enterprise customers including six of the world's top ten pharmaceutical firms from its Singapore headquarters.
Ownership category
akta.pro rank

ChemLex industry classification

Industry
Product category
AI-Driven Drug Discovery and Automated Chemical Synthesis
NAICS
Medical Laboratories (621511)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAIAD
Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations)

Keywords

  • AI-driven drug discovery
  • Automated chemical synthesis
  • AI retrosynthesis platform
  • High-throughput experimentation
  • Contract research services

Where ChemLex is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices3 records

Markets served

ChemLex business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. AI-driven chemical discovery platform services: ChemLex provides AI-powered chemical synthesis and discovery services to pharmaceutical and chemical companies through its autonomous chemistry platform. The company serves over 70 customers including six of the top ten pharmaceutical firms globally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

ChemLex product offering

Product offering

Core offering

ChemLex operates an AI-driven chemical synthesis contract research organization that delivers compounds to clients using proprietary AI retrosynthesis models and a high-throughput automated wet lab platform. The platform combines a dry lab of AI models for retrosynthesis planning, reaction condition recommendation, and LCMS spectrum interpretation with a fully automated wet lab that conducts up to 1000+ reactions per day in a closed-loop system. The company serves pharmaceutical, biotechnology, chemicals, semiconductors, and automotive clients with a 24/7 self-driving drug discovery laboratory.

Product overview

ChemLex offers an integrated AI-for-science platform combining a dry lab of proprietary AI models with a fully automated wet lab. The dry lab comprises three core AI modules: RetroPlanner (AI retrosynthesis for designing synthetic routes), Reaction Condition Recommender (generating optimal reaction conditions), and LCMS AutoAnalyzer (interpreting spectra and recommending purification). The wet lab provides five interconnected automation platforms: High-Throughput Experimentation (HTE), Auto-Analytical, Auto-Separation, Auto-Work-up, and Auto-Flow Chemistry — all feeding a closed-loop system where robots collect experimental data that continuously trains the AI models. The company operates a 24/7 self-driving drug discovery laboratory in Singapore, serving over 70 customers including six of the world's top ten pharmaceutical firms. Partnerships, including an MoU with Merck KGaA, expand the platform's reach into life science and electronics research workflows.

Differentiator

Problem solved

Functional benefit

Products and services

  • RetroPlanner AI retrosynthesis model that autonomously designs optimal synthetic routes for target molecules for pharmaceutical and chemical industry clients.
  • Reaction Condition Recommender AI module that recommends optimal reaction conditions for chemical synthesis, integrated into ChemLex's closed-loop AI and automation platform.
  • LCMS AutoAnalyzer AI-powered module that automatically interprets LCMS spectra and recommends purification conditions, operating as part of ChemLex's dry lab analytical capabilities for chemistry research customers.
  • High-Throughput Experimentation (HTE) Platform Wet lab automation platform supporting 8/40/500 mL reaction vials, heating and light reactions, capable of conducting up to 1000+ reactions per day for chemical synthesis customers.
  • Self-Driving Drug Discovery Laboratory 24/7 autonomous chemistry laboratory in Singapore combining AI-driven dry lab models with fully automated wet lab operations to accelerate pharmaceutical chemical discovery for customers including six of the world's top ten pharmaceutical firms.

Quantifiable outcome

  • 1000+ reactions per day capacity
  • +2 more outcomes

Companies that use ChemLex

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

ChemLex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

ChemLex partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Merck KGaAcoreStrategic or Co-development Partner · 20 January 2026Merck and ChemLex signed a Memorandum of Understanding to collaborate on advancing automated chemistry and research workflows in life science and electronics. The partnership aims to integrate AI-driven automation to accelerate discovery and innovation.
  • Merck KGaAcoreStrategic or Co-development Partner · 20 January 2026Merck KGaA is using AI as a critical enabler for drug and materials discovery and has signed an MoU with ChemLex Ltd. for AI-driven automated chemical synthesis.
  • Singapore's Experimental Drug Development CentrecoreStrategic or Co-development Partner · 8 December 2025ChemLex signed a memorandum of understanding with Singapore's Experimental Drug Development Centre to advance next-generation small molecule drug discovery through AI-driven automation.

Scale indicators5 records

Recent moves12 records

Expansion highlights6 records

ChemLex competitors and assessment

Company assessment

Direct peers

  • Schrödinger: Publicly listed AI-driven computational chemistry and molecular simulation platform serving pharma customers. Directly comparable to ChemLex in retrosynthesis, reaction prediction, and drug-discovery AI capabilities, though Schrödinger is more software-centric without integrated wet-lab robotics at ChemLex's scale.
  • XtalPi: China-founded AI + robotics drug discovery company combining computational chemistry with automated wet-lab experimentation. Closest direct peer to ChemLex in combining dry-lab AI models with high-throughput robotic synthesis, also serving global pharma customers.
  • Insilico Medicine: AI-driven drug discovery company applying generative AI and deep learning to target identification, chemistry, and clinical development. Comparable to ChemLex in pursuing AI-for-pharma, with overlapping pharma customer base and similar end-to-end platform ambition.
  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine-learning models in a closed-loop platform. Directly comparable to ChemLex's dry-lab/wet-lab integration model, though Recursion's pipeline is more biased toward phenotypic screening and internal pipeline development.
  • Exscientia: AI-driven precision medicine company applying AI to small-molecule drug design and discovery with major pharma partnerships. Comparable to ChemLex in serving top-tier pharma customers with AI-generated compounds, though with less emphasis on integrated wet-lab automation.
  • Atomwise: AI-based small-molecule drug discovery company using convolutional neural networks for hit identification and optimization. Comparable to ChemLex in applying AI to chemistry and pharma R&D, with a similar enterprise sales motion into pharma customers.

Emerging players

  • LabGenius: AI-driven protein engineering company combining machine learning with robotic wet-lab experimentation in a closed-loop system. Closely analogous to ChemLex in dry-lab/wet-lab integration, though focused on biologics rather than small-molecule synthesis.
  • Synthace: Cloud-based lab automation platform enabling high-throughput experimental workflows in life sciences. Comparable to ChemLex in automating wet-lab chemistry, though focused on workflow software rather than AI retrosynthesis or integrated service delivery.
  • Chemspeed Technologies: Provider of high-throughput automated synthesis workstations and robotic platforms for chemistry R&D. Comparable to ChemLex in providing automated synthesis infrastructure, though Chemspeed is primarily a tools vendor rather than a service provider.
  • Iambic Therapeutics: AI-driven drug discovery company combining physics-based modeling with generative AI for small-molecule design. Comparable to ChemLex in AI-pharma focus and use of internally generated data to improve models, with a similar enterprise-customer motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ChemLex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ChemLex leadership team

Management profile

Number of profiles

ChemLex funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ChemLex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ChemLex

What does ChemLex do?

ChemLex operates an AI-driven chemical synthesis contract research organization that delivers compounds to clients using proprietary AI retrosynthesis models and a high-throughput automated wet lab platform. The platform combines a dry lab of AI models for retrosynthesis planning, reaction condition recommendation, and LCMS spectrum interpretation with a fully automated wet lab that conducts up to 1000+ reactions per day in a closed-loop system. The company serves pharmaceutical, biotechnology, chemicals, semiconductors, and automotive clients with a 24/7 self-driving drug discovery laboratory.

Is ChemLex a public or private company?

ChemLex is a private company. It is classified as venture growth investor backed and is currently operating.

When was ChemLex founded?

ChemLex was founded in 2022. It employs 11 to 50 people.

Where is ChemLex based?

ChemLex is headquartered in Singapore, Singapore, in the Asia region.

How does ChemLex make money?

One revenue line is on record: AI-driven chemical discovery platform services.

Who are ChemLex's main competitors?

Direct peers on record are Schrödinger, XtalPi, Insilico Medicine, Recursion Pharmaceuticals, Exscientia and Atomwise. Emerging players are LabGenius, Synthace, Chemspeed Technologies and Iambic Therapeutics.

Does ChemLex have an API?

No public API is recorded for ChemLex.

What industry is ChemLex in?

ChemLex's product category is AI-Driven Drug Discovery and Automated Chemical Synthesis. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 621511 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EdbAI-for-science startup ChemLex raises USD 45M, launching self-driving lab for drug discovery in SingaporeChemLex, an AI-for-science startup, raised $45M led by Granite Asia and set up its global headquarters and self-driving lab in Singapore. The company, founded in 2022, serves over 70 customers, including six of the world's top ten pharma firms. It signed an MOU with Singapore's EDDC to accelerate drug discovery.The Business TimesChinese-founded, Singapore-based AI startups: The next Manus might be on this listManus became Singapore's first billion-dollar AI startup after being acquired by Meta in a landmark deal, though the Chinese founding team originally started the company in China before relocating headquarters to Singapore in 2025 to navigate US-China tensions. Tech in Asia has compiled a list of 16 Chinese-founded AI companies currently operating in Singapore that are gaining traction with high-profile clients, top-tier investors, and significant GitHub engagement. Key investors in these companies include Granite Asia, which backs three portfolio companies (Chemlex, Singdata, and Wiz.ai), while Peak XV Partners, Singtel Innov8, Sinovation Ventures, and ZhenFund each back two companies, with most founders having held senior roles at China's top tech firms, particularly Alibaba.EUROMETALShifting paradigms: AI reinvents established industry processesAccording to the Accelerating Discovery: AI Trends in Materials R&D Report by Matlantis Corp., nearly half of all R&D teams in the energy, chemicals, semiconductors and automotive sectors now use AI in some capacity, with AI and machine-learning methods driving an average of 46% of all simulation workloads as companies shift from experimental trials to computational approaches. Multiple chemical companies are actively integrating AI across their operations: Syensqo SA has developed its own AI policy, chatbot (SyGPT), and partnerships with Microsoft and Mohammed VI Polytechnic University, while Merck KGaA is using AI as a critical enabler for drug and materials discovery and has signed an MoU with ChemLex Ltd. for AI-driven automated chemical synthesis. Barriers remain, however, including universal concerns around IP security for sensitive research, with only 14% of survey respondents expressing high confidence in AI-generated simulation results, pointing to a need for greater validation and transparency.PR NewswireMerck et ChemLex signent un protocole d'accord pour faire progresser la chimie automatisée et l'innovation technologiqueMerck and ChemLex signed a memorandum of understanding to explore strategic collaboration in automated chemistry and AI-driven chemical synthesis for R&D in life sciences and electronics. The partnership aims to integrate ChemLex's 24/7 AI-powered automated synthesis platform with Merck's scientific expertise to improve the speed, efficiency, and reproducibility of early-stage discovery and development workflows. The parties will initially focus on identifying high-impact chemistry programs and evaluating pathways toward future formal collaboration.PR NewswireMerck and ChemLex Sign Memorandum of Understanding to Advance Automated Chemistry and Technological InnovationMerck and ChemLex have signed a Memorandum of Understanding to collaborate on advancing automated chemistry and research workflows in life science and electronics. The partnership aims to integrate AI-driven automation to accelerate discovery and innovation.EdbArtificial Intelligence in Singapore for businesses – a round-up from October to December 2025Singapore's government agencies have attracted multiple multinational and mid-sized companies to establish AI operations in the city-state during Q4 2025, with initiatives including AI Centers of Excellence, research labs, and innovation hubs generating hundreds of high-value jobs. Key announcements include Google DeepMind opening its first Southeast Asia research lab, Bain & Company launching an AI Innovation Hub, Workato establishing its first non-US AI lab, Manulife creating an AI CoE for insurance functions, and ChemLex opening a self-driving drug discovery laboratory backed by a US$45 million funding round. Singapore also launched a call for applications for a second data center offering at least 200MW capacity to support growing AI and cloud infrastructure demands.The Business TimesAs global scrutiny grows, Chinese firms look to call Singapore homeA growing number of Chinese companies are relocating to Singapore to shield themselves from US-China geopolitical tensions, a trend dubbed "Singapore washing" that has accelerated since President Trump's first term and now spans critical minerals, tech, and biotechnology sectors. While Singapore offers lower US tariffs of 10%, trusted global branding, and neutrality, firms like Shein and TikTok have found that domicile alone does not insulate them from Western regulatory scrutiny, and the strategy works better for smaller entities than large corporations. Singapore-based companies cited in the article include Terahop, DayOne, Manus AI, ChemLex, and Megaspeed, with the latter facing a US probe for allegedly diverting restricted Nvidia chips.ReutersAs global scrutiny grows, Chinese firms look to call Singapore homeA growing number of Chinese companies are relocating operations to Singapore to mitigate risks from Sino-U.S. geopolitical tensions, with demand rising 15-20% year-on-year according to InCorp Group CEO KG Tan. Companies including Terahop (backed by Zhongji Innolight), DayOne (spun off from GDS Holdings), Manus AI (from China's Butterfly Effect), and ChemLex have established Singapore operations, attracted by the city-state's trusted brand, 28 free trade agreements, and lower U.S. tariffs of just 10%. However, experts note this "Singapore washing" strategy primarily benefits smaller firms, as larger companies like Shein and TikTok have continued to face Western regulatory scrutiny despite relocating their headquarters.Pulse 2.0ChemLex: $45 Million Raised To Open Singapore Headquarters And Self-Driving Lab For Drug DiscoveryChemLex, an AI-for-science company focused on accelerating chemical discovery for the pharmaceutical industry, has established its global headquarters and a self-driving laboratory in Singapore while closing a $45 million funding round led by Granite Asia. Founded in 2022, the company has grown to serve more than 70 customers worldwide, including six of the world's top ten pharmaceutical companies, using its 24/7 autonomous chemistry system to compress synthesis and optimization timelines. As part of the expansion, ChemLex signed a memorandum of understanding with Singapore's Experimental Drug Development Centre to advance next-generation small molecule drug discovery through automation.The Manila TimesAI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in SingaporeChemLex announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside a USD 45 million funding round led by Granite Asia. The new funding will support expansion efforts, including hiring additional engineers and chemists to enhance the capability of its AI-driven drug discovery processes. The collaboration with the Experimental Drug Development Centre aims to accelerate the development of next-generation small molecule drugs through advanced automation.